Disease | Drug | Number of Patients | Results | Study Type | Reference |
---|---|---|---|---|---|
HL | Nivolumab | 23 | Confirmed safety and efficacy | Phase 1 | Ansell et al., 2015a |
HL | Pembrolizumab | 15 | Confirmed safety and efficacy | Phase 1b | Moskowitz et al., 2014 |
HL | Ipilimumab | 29 | Confirmed safety and efficacy | Phase 1 | Bashey et al., 2009 |
NHL | Pidilizumab | 17 total patients; DLBCL = 2; FL = 1 | Confirmed safety and efficacy | Phase 1 | Berger et al., 2008 |
FL | Pidilizumab | 32 | Confirmed safety and efficacy | Phase 2 | Westin et al., 2014 |
NHL | Pidilizumab | 66 total patients; DLBCL = 49; indolent B cell NHL = 13; mediastinal B cell lymphoma=4 | Confirmed safety and efficacy | Phase 2 | Armand et al., 2013 |
NHL | Ipilimumab | 18 total patients; FL = 14; DLBCL = 3; MCL = 1 | Confirmed safety and efficacy | Phase 1 | Ansell et al., 2009 |
MM | Pidilizumab | 17 total patients; MM = 1 | Long term stable disease in MM patient | Phase 1 | Berger et al., 2008 |
MM | Nivolumab | 82 total patients; MM = 27 | No response in the patients with MM | Phase 1 | Lesokhin et al., 2014 |
MM | Pembrolizumab | 34 | Safety and efficacy | Phase 1 | San Miguel et al., 2015 |
AML/MDS | Pidilizumab | 17 total patients; AML = 8; MDS = 1 | Minimal response in 1 AML patient | Phase 1 | Berger et al., 2008 |
AML, acute myeloid leukemia; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; HL, Hodgkin’s lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma.